The transition from G1 to S phase is the key regulatory step in the mammalian cell cycle. This transition is regulated positively by G1-specific cyclindependent kinases (cdks) and negatively by the product of the retinoblastoma tumour suppressor gene, pRb. Hypophosphorylated pRb binds to and inactivates the E2F transcription factor, which controls the expression of genes required for S-phase progression. Hyperphosphorylation of pRb in late G1 phase results in the accumulation of active E2F, a critical event in the progression to S phase. The E2F factor is not a single entity, but rather represents a family of highly related molecules, all of which bind to pRb or the pRb-related proteins p107 and p130.
Background
The most critical step in the regulation of the cell cycle occurs late in G1 phase, when cells must assess whether to irrevocably commit themselves to division. Elucidation of the molecular events governing this restriction point is therefore of critical importance to understanding the cell cycle. Much work has therefore centered on the G1-specific cyclins and their catalytic partners, the cyclin-dependent kinases (cdks), as candidate regulators of the G1 restriction point. These include the D-type cyclins (D1, D2 and D3), which associate with cdk4 or cdk6, and are first detected in mid-G1 phase, and the cyclin E-cdk2 complex, which is formed in late-G1 phase (reviewed in [1] ).
Much evidence has accumulated to indicate that a critical substrate through which the cyclin-cdk complexes control progression through the G1 restriction point is the product of the retinoblastoma gene, pRb (reviewed in [2] ). During most of G1, pRb is hypophosphorylated. At about the time that the restriction point is reached, pRb becomes hyperphosphorylated, and this state is maintained until the cell has undergone mitosis [2] , thus completing the cell cycle. Complexes regulated by cyclins D and E have been shown to phosphorylate pRb in vitro [3, 4] and are therefore potential candidates for the in vivo pRb kinase.
emphasized by the way oncoproteins of a number of DNA tumour viruses specifically target the hypophosphorylated form of pRb, releasing active E2F, hence favouring the execution of the G1/S transition (reviewed in [11] ).
The E2F factor is a heterodimeric complex, consisting of an E2F subunit and a DP subunit [12, 13] . Three distinct DP subunits have been reported to date [12, [14] [15] [16] [17] . DP-1 is the most widespread of these, and functions to regulate binding of the associated E2F subunit to DNA [15, 16] . Five E2F subunits have been characterized [6, [18] [19] [20] [21] [22] [23] [24] . All are structurally similar, consisting of a DNA-binding domain towards the amino terminus, an adjacent dimerization region and a carboxy-terminal transactivation domain. Within the transactivation domain, each E2F family member contains a discrete region which directs its association with a pRb family member: E2F-1, E2F-2 and E2F-3 interact with pRb in preference to p107 and p130 [6, 18, 19, 21, 25] , whereas E2F-4 and E2F-5 associate with p107 and p130 rather than pRb [22] [23] [24] . Changes in the cellular composition of E2F complexes containing each of these pRb-like proteins have been observed during the G1/S transition (reviewed in [2, 22] ).
Additional complexities in the control of the G1/S transition became apparent following the isolation of negative regulators of the cdks. Two families of mammalian cdk inhibitors have been identified (reviewed in [26] ). The first family consists of p16 Ink4 , p15 Ink4B , p18 Ink4C and p19 Ink4D [27, [28] [29] [30] [31] , each of which contains ankyrin repeats and can specifically inhibit the cyclin D-directed kinases, cdk4 and cdk6 [28] [29] [30] [31] [32] . The second family consists of p21 Cip1 , p27 Kip1 and p57 Kip2 [33] [34] [35] [36] [37] [38] [39] [40] . Members of this family share a region of sequence homology at their amino termini that is essential for their inhibitory activity. Using an in vitro assay, these proteins have been shown to inhibit multiple cyclin-dependent kinases [34, 35, 37, 38, 41] . Overexpression of members of either inhibitor family in mammalian cells leads to their arrest in the G1 phase of the cell cycle [28, 37, 38, 41, 42] .
Here, we use these cdk inhibitors to analyze the roles of the cdks and the different E2F family members in the regulation of the G1/S transition. We show that the cyclin D-cdk complexes are primarily involved in the release of E2F from pRb, an event which is known to induce entry into S phase. This event can be bypassed by the expression of E2F-1 but not E2F-4. The characterization of hybrid E2F proteins suggests that the difference between these two E2F family members is dictated by their DNAbinding domains. E2F-1 and E2F-4 thus seem to be able to interact with different subsets of E2F-responsive genes. In addition, free E2F is insufficient to drive cells into S phase under conditions where cyclin E-cdk2 activity is inhibited, indicating that the cyclin E-cdk2 holoenzyme plays an alternative role in the G1/S transition.
Results p16 arrests cells in G1 phase in a pRb-dependent manner
The strategy for our analysis uses the cdk inhibitors p16, p21 and p27. Of these G1-specific cdks, p16 only inhibits the catalytic subunits of the D-type cyclins, namely cdk4 and cdk6, whereas p21 and p27 inhibit cyclin D-and cyclin E-directed cdks. We investigated which molecules were able to overcome G1 arrests induced by these cdk inhibitors, specifically looking for differences between a p16-imposed blockade and a p21-or p27-induced arrest, because such differences would highlight the roles of each of the G1-specific cyclin-cdk holoenzymes.
The pRb-positive human osteosarcoma cell line, U2-OS, was transiently transfected with a plasmid encoding either wild-type p16 or a mutant p16 (with proline 114 replaced by leucine) that no longer interacts with its target cdks [42] , together with a plasmid encoding the cell-surface marker CD8 to allow subsequent detection of transfected cells. Cells were harvested after 48 hours and CD8 expression was detected using a monoclonal antibody coupled to Release of p16-imposed G1 arrest by DNA tumour virus oncoproteins and E2F-1. U2-OS cells were transfected with plasmids encoding the cell-surface marker CD8, p16, the viral oncoproteins or the E2F-1 derivatives, as indicated. Data are represented as the percentage change in the number of cells in G1 phase of the cell cycle, relative to the G1 population of cells transfected with the plasmid encoding CD8 only. The bars represent the average of at least three separate experiments, each performed in duplicate. Standard errors are displayed except where too small to depict clearly. At least 15 000 cells were gated for each sample. Untransfected cells displayed the following cell-cycle distribution: G1, 45 %; S, 23 %; G2/M, 32 %. + E 2 F -1 m u t a n t fluorescein isothiocyanate (FITC). Cells were then fixed, cellular DNA was stained using propidium iodide and cells were analyzed by fluorescence-activated cell sorting (FACS). Figure 1 shows that cells transfected with the plasmid encoding wild-type p16, but not the p16 mutant unable to bind to cdks, accumulated in the G1 phase of the cell cycle.
We next analyzed the effects of co-transfecting various viral oncogenes or the E2F-1 cDNA on this p16-imposed G1 arrest. Figure 1 shows that SV40 T antigen, adenovirus E1a and HPV16 E7 could completely or partially prevent the imposition of a G1 arrest by p16. These viral oncoproteins are known to disrupt complexes containing pRb family members (pRb, p107 and p130) and abrogate their restraining influence on the G1/S transition (reviewed in [11] ). A mutant form of E1a, with conserved region 2 was deleted (E1a⌬CR2 [43] ), which no longer interacted with pRb family members [44] , failed to release the p16-induced arrest (Fig. 1) . The plasmids encoding E1a and E1a⌬CR2 have been previously shown to direct the expression of similar amounts of protein [44] .
As an additional control, U2-OS cells were transfected with plasmids encoding E1a or E7 in the absence of p16. Cells transfected with these oncoproteins displayed essentially an identical cell-cycle profile to their untransfected counterparts (data not shown).
To define further the roles of the different members of the pRb family in this event, we used a variant of HPV E7, in which the LXCXE motif (single-letter amino-acid code; X is any amino acid), responsible for targeting complexes containing pRb-like proteins, was mutated to LXCXG [45] . This form of E7 cannot disrupt pRb complexes, but can interact with p107 (and presumably p130) [45, 46] , and has been previously shown to be expressed at similar levels to wild-type E7 [46] . As shown in Figure 1 , this construct was totally ineffective in releasing a p16-induced arrest, indicating that G1 arrest in these cells was linked specifically to the presence of functional pRb, and that it is pRb complexes (rather than those containing p107 or p130) that are essential for restraining the G1/S transition.
Of the proteins that interact with pRb through the pocket domain, evidence suggests the primary regulators of G1 progression are E2F family members. We therefore tested whether E2F-1 could prevent the accumulation of cells in G1 resulting from wild-type p16 overexpression. As shown in Figure 1 , E2F-1 was as effective as the viral oncoproteins in this respect, completely abolishing p16-induced accumulation of cells in G1 phase. This ability was dependent upon E2F-1's DNA-binding activity, because a mutant form of E2F-1 with no DNA-binding activity [47] was unable to prevent G1 arrest mediated by wild-type p16. This non-DNA-binding mutant was still able to bind pRb [47] , so the release of p16-induced G1 arrest was not due to the release of sequestered endogenous protein from pRb. These results provide evidence that E2F is the critical activity regulated by pRb, and cyclin D-cdk holoenzymes are essential for the generation of active, 'free' E2F in vivo.
We next performed arrest-release experiments using the more general cdk inhibitory proteins, p21 and p27 (Fig. 2) . Again, cells co-transfected with the plasmid encoding the CD8 marker and plasmids encoding either p21 ( V e c t o r E 2 F -1 E 2 F -1 m u t a n t E 1 a T a n t i g e n E 7 V e c t o r E 2 F -1 E 2 F -1 m u t a n t E 1 a T a n t i g e n E 7 p27 + p21 + % Change in cells in G1 phase % Change in cells in G1 phase
this arrest could be at least partially relieved by co-transfection with the plasmid encoding T antigen. However, the viral proteins that cause transformation primarily by disrupting pRb pocket protein interactions (E1a and E7) were ineffective in preventing G1 arrest upon co-transfection with p21 or p27. In addition, E2F-1 was also unable to suppress the arrests mediated by either p21 or p27.
The failure of E2F-1 to overcome a p21-or p27-imposed arrest was not a result of a block in its activity. Changes in E2F activity following transfection of U2-OS cells with plasmids encoding E2F-1 or SV40 T antigen were monitored using an E2F-dependent reporter (the chloramphenicol acetyltransferase (CAT) gene driven by the E2A promoter, E2A-CAT). An increase in E2F activity was detected regardless of whether the cells were co-transfected with plasmids directing expression of p16, p21 or p27 (Fig. 3 , bars labelled E2F-1); as an inhibitor-negative control, cells were transfected with the vector expressing the non-inhibitory mutant p16. As expected, the expression of T antigen also resulted in an elevation in E2F activity, and again the level of activation was not influenced by any of the inhibitors. Two conclusions follow from these results. Firstly, the failure of transfected E2F-1 to overcome p21-or p27-induced cell-cycle arrest was not due to any inhibition of its activity, implying that these cdk inhibitors block essential events unconnected with E2F-1 activation. Secondly, the enhancement of E2F activity induced by T antigen was not the only event leading to partial release of the p21-or p27-mediated arrest, because co-transfection of the plasmid encoding E2F-1 led to a similar elevation in E2F-driven transcription but failed to release the arrest.
Taken together, the results of the experiments using the cdk inhibitors indicate that the primary function of cyclin D-cdk4 or cyclin D-cdk6 complexes, whose activity is specifically inhibited by p16, is to release sequestered E2F from pRb, and that cyclin E-cdk2 is required to perform some other function in the transition from G1 to S phase. Unlike p27, the p21 protein is also able to bind to proliferating cell nuclear antigen (PCNA) [48] , and thereby prevent DNA replication [49, 50] . Because we observed identical effects when p21 or p27 were expressed, these results must be independent of the interaction between p21 and PCNA.
E2F family members have different abilities to release a p16-induced G1 arrest
The results with DNA tumour virus oncoproteins ( Fig. 1 ) indicated that complexes containing pRb, rather than those containing p107 (or p130), were important in regulation of the G1/S transition. One interpretation of these results was that E2F family members specifically regulated by p107 or p130, in contrast to those regulated by pRb, might be unable to promote progression into S phase in the presence of p16. We addressed this possibility by testing the ability of E2F-4, which is reg ulated in vivo by p107, to release a Elevated E2F-1 activity alone is insufficient to release a p21-or p27-imposed G1 arrest. U2-OS cells were transfected with plasmids encoding the E2A-CAT reporter, an inhibitor protein and either E2F-1 or SV40 T antigen. All transfections included a plasmid directing the expression of ␤-galactosidase. Cells were harvested and assayed for CAT activity, which was normalized for variable transfection efficiencies by correcting for ␤-galactosidase activity.
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p16-induced G1 arrest. Figure 4 clearly demonstrates that overexpression of E2F-4 was unable to prevent the p16-imposed G1 arrest. The inability of E2F-4 to release the G1 arrest was unlikely to result from its inactivation by endogenous p107, because it was able to transactivate an E2A-CAT reporter plasmid as efficiently as E2F-1 (see below).
To investigate the molecular basis for the differential abilities of E2F-1 and E2F-4 to release a p16-imposed G1 arrest, we constructed chimeric E2F molecules. Using a PCR-based approach, we introduced into the cDNA encoding E2F-4 a BglII site in the equivalent position to the unique BglII site in the E2F-1 cDNA immediately following the DNA-binding and dimerization domains. Two chimeric E2F proteins were then generated ( Fig. 5a ): in the first (E2F-1/4), the amino terminus of E2F-1, which contains the DNA-binding and dimerization domains, was fused to the carboxyl terminus of E2F-4, which contains the transactivation domain; in the converse construct (E2F-4/1), the amino terminus of E2F-4 was fused to the transactivation domain of E2F-1. These chimeric E2F molecules, like E2F-1, were epitope tagged at their amino termini with the hemagglutinin epitope and this property was used to analyze the levels of protein expression by these constructs. Western immunoblot analysis of transfected cells clearly indicated that equivalent levels of wild-type E2F-1 and other fusion proteins were synthesized (Fig. 5b) .
After analysis of expression levels, we tested the ability of these fusion proteins to activate the E2A-CAT reporter (Fig. 5c ). Both E2F-1 and E2F-4 were equally effective at activating this reporter. However, as shown previously [22, 23] , they differed in their sensitivity to repression by pRb and p107; E2F-1 was most sensitive to pRb inhibition, whereas E2F-4 was repressed by p107. Both fusion proteins were able to transactivate the reporter. Furthermore, as expected, the fusion proteins were inhibited by pRb or p107, depending on the nature of their transactivation domains (Fig. 5c) . Thus, E2F-1/4 was repressed by p107 but not by pRb, whereas E2F-4/1 was inhibited by pRb but not by p107. This clearly demonstrates that, in transfected U2-OS cells, each of the E2F constructs directed the expression of equivalent amounts of active E2F protein. Both of these fusion proteins were then used in the p16 arrest-release assay. Figure 5d shows that E2F-1/4 was effective in preventing the p16-induced arrest, whereas E2F-4/1 was not. Thus, the release from arrest was dependent upon the presence of the amino terminus of E2F-1.
pRb phosphorylation status in arrested and released cells
We addressed the question of the phosphorylation status of pRb in arrested and released cells. U2-OS cells were transfected with plasmids encoding CD8, wild-type p16 and either wild-type E2F-1 or the non-DNA binding mutant. Cells were harvested and transfected cells were tagged with FITC via antibodies against the CD8 surface marker. FITC-labelled cells were then physically separated from the bulk untransfected population of cells by FACS, and only cells with a greater than 100-fold enhancement of fluorescence, compared to untransfected cells, were retained in the CD8-positive population. Western blots were performed on the sorted cells to analyze the pRb banding pattern, which is indicative of its phosphorylation status. As shown in Figure 6 , cells cotransfected with plasmids expressing wild-type p16 and mutant E2F-1 arrested in G1 phase and contained pRb which migrated primarily as a single band of 105 kDa, characteristic of the hypophosphorylated protein. This is in contrast to the untransfected cells, in which pRb migrated largely as a mixture of high molecular weight species, diagnostic of the hyperphosphorylated protein.
Cells co-transfected with plasmids expressing p16 and wild-type E2F-1 displayed a cell-cycle profile indistinguishable from that of untransfected cells. However, examination of the pRb in these cells demonstrated that it was predominantly in the hypophosphorylated form. Therefore, cells released from the p16 arrest by expression of E2F-1 can traverse the G1/S boundary by bypassing the requirement for concomitant phosphorylation of pRb.
Discussion
The results described above are consistent with the transition from G1 to S phase of the cell cycle being achieved by the execution of two distinct events. One of these is governed by the cyclin D-directed kinases and is primarily involved in the generation of 'free' E2F-1-like activity. This is achieved when the cyclin D-cdk holoenzymes phosphorylate pRb [3, 4] , and possibly also E2F-1 (D.J.M . and N.C.J., unpublished observations), thereby precluding the formation of inhibitory pRb-E2F complexes. The 'free' E2F-1-like activity is then able to transactivate its target genes, hence facilitating entry into S phase. The 'free' E2F generated must display the DNA-binding specificity of E2F-1, as overexpression of E2F-4 was not effective in releasing a p16-induced arrest. The release of the p16 arrest by E2F-1 is unlikely to be because E2F-1 up-regulates cyclin D or cdk4 expression, because elevated E2F-1 levels have been shown to have no effect on the expression of these kinase components [51] . In addition, the demonstration that pRb remains hypophosphorylated in cells released from a p16-mediated arrest by E2F-1 also argues against the presence of active cyclin D-cdk complexes in these cells.
Although elevated E2F-1 activity alone is sufficient to release a p16-imposed G1 arrest, it is insufficient to release the G1 arrest in cells overexpressing p21 or p27. This implies one of two possibilities. The first possibility (Fig.   7a ) is that cyclin E-cdk2 activation may occur downstream of E2F-1, but the endogenous mechanism by which cyclin E-cdk2 is activated is not sufficiently powerful to overcome the exogenous p21-or p27-induced arrest. However, we found that the E2F activity obtained when plasmids expressing p21 (or p27) and E2F-1 were co-expressed (and the cells were arrested) was similar to that found in cells co-transfected with plasmids encoding p21 (or p27) and SV40 T antigen (these cells were partially released from arrest). This would suggest that 'free' E2F is not directly activating cyclin E-cdk2 complexes, or if it is, it is not sufficient to overcome the p21-(or p27-) mediated inhibition.
The second possibility consistent with our data (Fig. 7b) is that cyclin E-cdk2 lies on an alternative pathway to E2F-1; both of these pathways would then need to be triggered to execute the G1/S transition. This model would be consistent with that proposed by Restnitzky and Reed [52] , based on the analysis of the timing of S-phase entry in cells expressing cyclin D1 and/or cyclin E from inducible promoters. Expression of either cyclin alone caused a small reduction in the time required to proceed from G0 into S phase, indicating that both cyclins D1 and E are rate limiting for this transition. However, expression of both cyclins
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Figure 5
The release of the p16-imposed arrest is due to the presence of the E2F-1 DNA-binding domain. together caused a synergistic reduction in the duration of the G0 to S transition, demonstrating that the two cyclins function on separate pathways [52] . Our data are entirely consistent with this model, and further demonstrate that the crucial factor activated by the cyclin D-dependent branch of this scheme is an E2F-1-like activity.
Results from other experimental systems have recently emerged supporting the view that the pathway involving pRb, E2F, cyclin D, cdk4/6 and p16 is involved in controlling the G1/S transition. Microinjection of antibodies against cyclin D1 arrests pRb-positive cells in G1 phase [53, 54] . However, when the same experiments are performed in cell lines where pRb function is either abrogated by mutation or compromized by expression of a neutralizing oncogene, such as SV40 T antigen, cells cycle normally, indicating that cyclin D-cdk complexes are not essential for G1 progression in these cells [53, 54] . Cells that do not produce functional pRb are also insensitive to arrest by p16 [42] . Mutation of pRb renders it unnecessary to disrupt pRb-E2F complexes by cyclin D-directed phosphorylation.
Similar experiments have been performed recently with antibodies against cyclin E. In this case, all cells tested arrested in G1, irrespective of their pRb status [55] . Such data indicate that cyclin D-cdk, but not cyclin E-cdk2, acts upstream of pRb. The critical targets regulated by cyclin E-cdk2 are as yet unknown. They must, however, be independent of proteins that bind to the pocket domain of pRb, because adenovirus E1a and HPV E7, which disrupt pRb complexes, were unable to release a p21-or p27-mediated G1 arrest (Fig. 2) , and cells released from a p16-induced arrest by co-expression of E2F-1 are able to cycle with pRb in the hypophosphoryla ted state (Fig. 6) .
Recently, DeGregori et al. [56] have also demonstrated that overexpression of E2F-1 can prevent a p16-mediated cell-cycle arrest. However, in contrast to our data, these
Figure 7
Model representing potential routes through the G1/S transition (see text for details). Cycling authors suggest that such overexpression can also release a p21-or p27-mediated arrest. The reasons for this discrepancy are unclear at present.
Because of its central role in the restraint of entry into S phase, the identification of the physiological pRb kinase has received considerable attention. Our demonstration that cells co-expressing p16 and E2F-1 cycle with pRb in the hypophosphorylated state indicates that cdk4 and cdk6, the catalytic partners of the D-type cyclins, play a central role in pRb phosphorylation. Previous studies in which cyclin D1 or cyclin E are ectopically expressed from an inducible promoter have demonstrated that phosphorylation of pRb correlates with the induction of cyclin D1, rather than cyclin E [52] . The pRb protein has also been shown to be the preferred substrate for cyclin D-directed cdks in vitro, although in vitro hyperphosphorylation of pRb can also be achieved by cyclin E-cdk2 as well as cyclin A-cdk2 (reviewed in [2] ).
Our data also demonstrate that the critical factor regulated by pRb is an E2F-1-like activity. Overexpression of E2F-1 alone is able to bypass the requirement for hyperphosphorylation of pRb and induce entry into S phase. It could be argued that, by overexpressing E2F-1, other pocketbound proteins are competed from pRb by the excess E2F-1, and it is these proteins that are then able to trigger the G1/S transition. This possibility can be excluded, however, because overexpression of the non-DNAbinding E2F-1 mutant was completely unable to release the p16-imposed arrest. This mutant is unchanged in its ability to interact with pRb [47] . Thus, in U2-OS cells, E2F-1-like family members are the essential pRbregulated factors required for the G1/S transition. Other pRb-binding proteins, such as c-abl, c-Myc and ATF-2, may play a supportive role during the progression into S phase, but their activities are not sufficient for this process.
Our results also highlight functional differences between the E2F family members, in that E2F-1, but not E2F-4, was able to prevent a p16-imposed G1 arrest. This difference is unlikely to be a result of the relative strengths of the transactivation domains of these two transcription factors. When the E2F-4 transactivation domain was fused to the E2F-1 DNA-binding/dimerization region, it was slightly more potent in its ability to activate an E2A-CAT reporter than wild-type E2F-1 (Fig. 5c) . Also, Hijmans et al. [24] have demonstrated that the transactivation domains of these two E2F family members are equally effective in reporter assays when fused to a heterologous DNA-binding domain.
Our experiments with chimeric E2F proteins indicated that the amino-terminus of E2F-1 was essential to prevent a p16-induced arrest. This region contains the DNA-binding and dimerization domains, as well as a site that is involved in interacting with cyclin A [57, 58] . Although our results do not directly distinguish between the importance of these different domains, it is likely that the effect is due to the DNA-binding portion of the molecule alone. The dimerization domain is unlikely to be involved, because both E2F-1 and E2F-4 seem to display no specificity in the selection of their heterodimerization partners [12] . Similarly, the cyclin A-interaction site is unlikely to be the basis for the different activities, because this interaction is important for down-regulating E2F-1 activity during the S/G2 phase of the cell cycle, rather than the G1/S transition [57, 58] . Thus, the difference between E2F-1 and E2F-4 seems to be attributable to their relative DNA-binding specificities. The DNAbinding domains do, however, display significant structural homology and indeed, one means by which E2F-4 was isolated involved a strategy based on the sequence conservation in the DNA-binding region of the E2F family members [22, 23] .
Some differences in the DNA-binding specificity of E2F-1 and E2F-4 have been indicated previously. In comparison to E2F-1, E2F-4 was inefficient in transactivating a synthetic promoter containing four E2F-binding sites driving a CAT reporter [16, 22] . In vivo, E2F-binding sites in certain promoters seem to be regulated by either pRb or p107, indicating the involvement of different E2F family members (reviewed in [2] ). Here, we have demonstrated a functional difference between the DNA-binding domains of E2F-1 and E2F-4 in vivo. Thus, it seems likely that E2F-1 and E2F-4 will transactivate different subsets of responsive genes.
The finding that E2F-1 but not E2F-4 could release the p16-induced G1 arrest also substantiates the observation that dysregulation of components of the pRb pathway can lead to uncontrolled proliferation. Thus, many genetic changes in the components of the pRb pathway (pRb itself, cyclin D1, p16 and cdk4) have been associated with cancerous outgrowth [2, 59, 60] . No predisposing mutations in components of the p107 or the p130 pathways have been described to date, despite extensive investigation, indicating the pre-eminence of the pRb pathway in the regulation of the G1/S transition. SV40 T antigen could release both p16-and p21/p27-imposed arrests (Figs 1,2) , and release from both types of arrest was accompanied by elevations in the endogenous E2F activity (Fig. 5) . On its own, however, this elevation in E2F activity was not sufficient to release the p21-or p27-induced G1 arrests. This result indicates that SV40 T antigen must possess some additional property which enables it to overcome the effects of p21 and p27. We are currently investigating this T-antigen specific function using mutant forms of the protein.
Conclusions
In summary, we have provided evidence that the transition from G1 into S phase is controlled by two parallel pathways: one involves cyclin E-cdk2, and is independent of pRb and E2F; the other requires the phosphorylation of pRb by cyclin D-cdk complexes in order to generate 'free', active E2F. The cellular requirement for pRb phosphorylation normally associated with the G1/S transition can be abolished if E2F-1 is overexpressed, indicating that E2F is the major factor regulated by pRb. Also, the observation that E2F-1, but not E2F-4, can release a p16-imposed G1 arrest, and that this ability is most probably conferred by the DNA-binding domain of E2F-1, indicates that these two E2F family members may transactivate different sets of genes.
Materials and methods
Plasmid constructs
The plasmids used to express the following proteins have been described elsewhere: SV40 T antigen [61] , adenovirus E1a and E1a⌬CR2 [43] , HPV16 E7 and the E7 LXCXG mutant [45, 46] , E2F-1 [62] and E2F-4 [22] . The cDNAs encoding p16, p21 and p27 were gifts from G. Peters; each was cloned into the mammalian expression vector pJ7⍀ [63] .
To construct E2F-1/4, PCR was performed using E2F-4 cDNA [22] as template and the oligonucleotides 5′-GCGCAGATCTGCACACTCTTC-AGGTGAATCTGG-3′ and 5′-GCGCGGATCCACCATGGCGGAGG-CCGGGCCACAGG-3′. The resulting fragment was digested with BamHI and BglII and ligated into plasmid pcDNAI-HA-E2F-1 [62] cut with the same enzymes. To construct E2F-4/1, PCR was performed using E2F-4 cDNA as template and oligonucleotides 5′-GCGCA-GATCTCCATTGAGGTTCTGCTGGTGAACAAGG-3′ and 5′-GCGC-GAATTCAGAGGTTGAGAACAGGCAC-3′. The resulting fragment was digested with EcoRI and BglII and ligated into pcDNAI-HA-E2F-1 [62] cut with the same enzymes.
Cell culture, transfection and FACS analysis
U2-OS cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10 % fetal calf serum. Cells were transfected as described [64] . Each transfection experiment was performed at least three times with different batches of DNA. Cells, plated in 9 cm dishes, were transfected with the following amount of plasmid per dish: CD8, 0.5 µg; p16, p21 or p27, 2.5 µg; other effector plasmids, 10 µg. Cells transfected for reporter assays were processed as described [65] , and transfection efficiency was monitored by including 2 g pJATLAC in each transfection and assaying extracts for ␤-galactosidase activity [66] .
For FACS analysis, cells were harvested 48 h after transfection by incubation with 0.5 % trypsin, 0.02 % EDTA in phosphate buffered saline, and were subsequently collected by centrifugation at 1000 rpm for 3 min at 4 o C. Cells were washed once with solution I (3 % bovine serum albumin, 0.02 % sodium azide in phosphate buffered saline) and resuspended in 300 l solution I containing 0.2 g FITC-conjugated anti-CD8 antibody (DAKO A/S, Denmark). Antibody binding was allowed to proceed for 45 min on ice, after which cells were washed 3 times with 5 ml solution I. Following the final wash, cells were resuspended in 300 l 0.02 % sodium azide in phosphate buffered saline and then 700 l absolute ethanol was added to fix the cells. Cells were then stained with propidium iodide and FACS analysis was performed using a Becton Dickinson FACS Vantage.
Western immunoblotting
Western analysis was performed as described by Harlow and Lane [67] using the G3-245 anti-human pRb antibody (Pharmingen, San Diego, USA). or the 12CA5 anti-hemagglutinin antibody (Boehringer Mannheim, Germany). The signal was detected using anti-mouse IgG-horse radish peroxidase-conjugated antibody and Enhanced Chemiluminescence (Amersham, UK).
